Across TCGA pan-cancer cohorts, RBMY2CP RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RBMY2CP data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RBMY2CP RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RBMY2CP expression acts as an unfavorable survival marker.

OV and ESCA are the cancer types where RBMY2CP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	II,III,IV	0.021	0.844	<.001	108	view →
ESCA	DFS	Tertile	All	0.147	0.536	.006	27	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RBMY2CP tumor-vs-normal RNA expression · all RBMY2CP data types